Atlas Trials

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

Clinical trial NCT06192680 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06192680
Sponsor
Harbin Medical University
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Colorectal Cancer
Start date
2024-04-01
Primary completion
2025-11-30
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.